Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma
Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma
复制标题
DOI：
10.1080/10428194.2017.1324161
复制
发表时间：
2018-01-01
影响因子：
2.6
通讯作者：
Tripepi, Giovanni
中科院分区：
文献类型：
--
作者：
Milone, Giuseppe;Martino, Massimo;Tripepi, Giovanni
我们在此报告一项 II/III 期前瞻性研究的最终结果，该研究评估了在多发性骨髓瘤中使用按需普乐沙福 (PLX) 添加到动员化疗中，以治疗出现动员失败预测迹象的患者。共有111名MM患者登记，均接受环磷酰胺4 g/m(2)和粒细胞集落刺激因子（G-CSF）治疗。总体而言，97.2% (108/111) 的患者成功动员了 CD34+ 细胞。 97.2% (108/111) 实现最低收获 (>= 2.0 x 10(6) CD34+ 细胞/kg)，84.6% (94/111) 实现最佳收获成功率 (>= 4.0 x 10(6) CD34+ 细胞/kg)。多变量分析显示，与未使用任何 PLX 的历史对照组相比，接受按需 PLX 治疗的患者成功实现最小收获 (p = .006) 和最佳收获 (p = .05) 的可能性显着更高。成功实现最小收获的概率每增加 1%，增量成本效益比为每位患者 40.6（原文如此）。
We here report final results of a phase II/III prospective study that evaluated in Multiple Myeloma the use of on-demand plerixafor (PLX) added to mobilizing chemotherapy for patients showing predictive signs of mobilization failure. A total of 111 patients with MM were registered, all received cyclophosphamide 4 g/m(2) and granulocyte colony-stimulating factor (G-CSF). Overall, a successful CD34+ cell mobilization was achieved in 97.2% (108/111) of patients. Minimum harvest (>= 2.0 x 10(6) CD34+ cells/kg) was achieved in 97.2% (108/111) and optimal harvest success (>= 4.0 x 10(6) CD34+ cells/kg) was achieved in 84.6% (94/111). Multivariate analysis showed that patients who received on-demand PLX treatment had significantly higher likelihoods of successfully achieving both the minimal (p = .006) and optimal harvest (p = .05) in respect to a historical control group mobilized without any PLX. The incremental cost-effectiveness ratio, for each 1% increase in probability of achieving a successful minimal harvest, was (sic)40.6 per patient.